Hans Georg Lerchen

Company: Vincerx Pharma

Job title: Chief Scientific Officer

Seminars:

Exploring VIP236, an avß3-Integrin-targeted Small Molecule Drug Conjugate with a Tailored Design of Linker & Metabolite Profile 11:30 am

avß3-integrin targeted SMDC for the treatment of multiple cancer types Reviewing linker design for efficient cleavage by tumor associated neutrophil elastase Assessing a modified camptothecin payload with high permeability and low efflux ratioRead more

day: Day Two